One hundred patients scheduled for MRM were screened for eligibility, and 76 participants were enrolled (Fig. 1). Two patients lost contact, five patients refused to conduct a questionnaire survey during follow-up, one patient developed tumor recurrence, and the other patient was seriously ill and died within 6 months after surgery. All the above patients were withdrawn from the follow-up study.
There were no significant differences in the CRP, IL-6, or WBC values between the two groups on the day before the operation. The median (IQR) CRP, IL-6, and WBC values were 24 (20.75–26.25) mg/l, 25.35 (19.3-29.675) pg/ml, and 12 (11–13)×109/l, respectively, in group C vs 12 (10-13.25) mg/l, 10.45 (9.575–11.65) pg/ml, and 9 (7.75–9.25)×109/l, respectively, in group PT, p < 0.001, on the first day after the operation. On the third day after the operation, the WBC and IL-6 values in the two groups recovered to normal levels before the operation, and there were no significant differences between the two groups. However, the median (IQR) CRP level was 11 (8-12.25) mg/l in group C vs 4 (2.75-5) mg/l in group PT, p < 0.001. The median (IQR) blood glucose level at the end of the operation was 7.8 (7.5–8.4) mmol/l in group C vs 5.4 (5.3–5.8) mmol/l in group PT, p < 0.001. The median (IQR) QOL score was 43 (41-51.5) in group C vs 53 (51.75-55) in group PT, p < 0.001. The incidence of chronic pain/all, n was 4/33 vs 0/34, p < 0.001. (Table 1)
The NRS pain scores (median (IQR)) were significantly lower in group PT at 0–48 hours: (1) at 3 h, 6 h, 12 h, 24 h, and 48 h activity 1 (0–1), 1 (0–1), 1 (1–2), 1 (1–1), 1 (1–1), respectively, vs 4 (3–5), 4 (3–5), 3 (3–4), 3 (2–3), 2 (1–2), respectively, p < 0.001; (2) at 3 h, 6 h, 12 h, 24 h, 48 h rest 0 (0–0), 0 (0–1), 0 (0–1), 1 (1–1), 1 (0–1), respectively, vs 3 (2.75–4), 3 (2.75–4), 3 (2–3), 3 (2–3), 1(1–2), respectively, p < 0.001. (Table 2)
There was no significant difference in the operation time. The median (IQR) length of stay was 6 (6–7) days in group C vs 5 (5–6) days in group PT, p < 0.001. The mean (SD) consumption of propofol and remifentanil was 907.2 (51.04) mg and 1473.1 (242.5) µg in group C vs 517.1 (116.1) mg and 506.1 (212.8) µg in group PT, with mean differences of 390.1 mg (95% CI 349.2 to 431.1, p < 0.001) and 967.2 µg (95% CI 862.9 to 1071.4, p < 0.001). The median (IQR) PONV score was 2 (1–2) in group C vs 1 (0–1) in group PT, p < 0.001. (Table 2)
No adverse events, which included pneumothorax, vascular puncture, and local anesthetic toxicity, were recorded.
Table 1. Patient characteristics, primary outcomes
|
|
Group C
|
Group PT
|
P value
|
Patient characteristic
Age, mean (SD)
|
46.8(7.4)
|
|
49.7(7.4)
|
0.183
|
BMI, kg/m2 (SD)
Primary outcome
CRP, mg/l (median (IQR))
Preoperative day
|
17.7(2.7)
3(2–4)
|
16.9(1.7)
3(2–4)
|
0.215
0.953
|
1 d after operation
3 d after operation
IL-6, pg/ml (median (IQR))
Preoperative day
1 d after operation
3 d after operation
WBC, ×109/l (median (IQR))
Preoperative day
1 d after operation
3 d after operation
Blood glucose, mmol/l (median (IQR))
|
24(20.75–26.25)
11(8-12.25)
2(1.275-2.6)
25.35(19.3-29.675)
3.9(2.55–4.525)
6(5–7)
12(11–13)
7(6–8)
|
12(10-13.25)
4(2.75-5)
2(1.275-2.6)
10.45(9.575–11.65)
3.15(2.4-4.025)
6(6–7)
9(7.75–9.25)
7(6–8)
|
< 0.001
< 0.001
1
<0.001
0.219
0.240
<0.001
0.392
|
Before anesthesia induction
the end of operation
QOL scores (median (IQR))
The incidence of chronic pain/all, n
|
5.2(5.1-5.425)
7.8(7.5–8.4)
43(41-51.5)
4/33
|
5.2(5.0-5.325)
5.4(5.3–5.8)
53(51.75-55)
0/34
|
0.318
<0.001
< 0.001
<0.001
|
|
Table 2. Secondary outcomes
|
|
Group C
|
Group PT
|
P value
|
NRS score
median at 3 h activity (IQR)
|
4(3–5)
|
1(0–1)1(0–1) |
< 0.001< 0.001
|
median at 6 h activity (IQR)
median at 12 h activity (IQR)
median at 24 h activity (IQR)
median at 48 h activity (IQR)
median at 3 h rest (IQR)
median at 6 h rest (IQR)
median at 12 h rest (IQR)
median at 24 h rest (IQR)
median at 48 h rest (IQR)
operation time, min (mean (SD))
|
4(3–4)
3(3–4)
3(2–3)
2(1–2)
3(2.75-4)
3(2.75-4)
3(2–3)
3(2–3)
1(1–2)
137.0(37.3)
|
1(0–1)
1(1–2)
1(1–1)
1(1–1)
0(0–0)
0(0–1)
0(0–1)
1(1–1)
1(0–1)
132.2(46.3)
|
<0.001
<0.001
< 0.001
<0.001
< 0.001
<0.001
<0.001
<0.001
<0.001
0.115
|
median length of stay (IQR)
consumption of propofol, mg (mean (SD))
consumption of remifentanil, µg (mean (SD))
press times of PCA pump at 0–24 hours
median (IQR)
press times of PCA pump at 24–48 hours
median (IQR)
median PONV score (IQR)
|
6(6–7)
907.2(51.04)
1473.1(242.5)
13(12–15)
14(13–15)
2(1–2)
|
5(5–6)
517.1(116.1)
506.1(212.8)
5(3–6)
6(5–8)
1(0–1)
|
<0.001
<0.001
<0.001
< 0.001
< 0.001
< 0.001
|